Search research articles
Contact Us
Filters
Showing results (101-110 of 134) with videos related to
Page
of 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 16, 2018
A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium
Stephanie Lheureux, Anna Tinker, Blaise Clarke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 16, 2023
Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Stephanie Lheureux, Stephenie D Prokopec, Leslie E Oldfield, et al.
Journal for Immunotherapy of Cancer
|
February 26, 2025
Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer
Vladimir Roudko, Diane Marie Del Valle, Emir Radkevich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2025
Genomic and epigenomic ctDNA profiling in liquid biopsies from heavily pre-treated patients with DNA damage response-deficient tumors
Ian M Silverman, Joseph D Schonoft, Benjamin Herzberg, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
June 21, 2023
Symptom screening with Targeted Early Palliative care (STEP) versus usual care for patients with advanced cancer: a mixed methods study
Camilla Zimmermann, Ashley Pope, Breffni Hannon, et al.
Genome Medicine
|
December 19, 2024
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib
Alan Barnicle, Isabelle Ray-Coquard, Etienne Rouleau, et al.
Journal for Immunotherapy of Cancer
|
June 15, 2022
Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab
Geoffrey Alan Watson, Enrique Sanz-Garcia, Wen-Jiang Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 30, 2020
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)
Neesha C Dhani, Hal W Hirte, Lisa Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 23, 2017
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization
Stephanie Lheureux, Zhongwu Lai, Brian A Dougherty, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 7, 2021
Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced Cancer
Camilla Zimmermann, Ashley Pope, Breffni Hannon, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 134) with videos related to
Sort By:
Page
of 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 16, 2018
A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium
Stephanie Lheureux, Anna Tinker, Blaise Clarke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 16, 2023
Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Stephanie Lheureux, Stephenie D Prokopec, Leslie E Oldfield, et al.
Journal for Immunotherapy of Cancer
|
February 26, 2025
Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer
Vladimir Roudko, Diane Marie Del Valle, Emir Radkevich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2025
Genomic and epigenomic ctDNA profiling in liquid biopsies from heavily pre-treated patients with DNA damage response-deficient tumors
Ian M Silverman, Joseph D Schonoft, Benjamin Herzberg, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
June 21, 2023
Symptom screening with Targeted Early Palliative care (STEP) versus usual care for patients with advanced cancer: a mixed methods study
Camilla Zimmermann, Ashley Pope, Breffni Hannon, et al.
Genome Medicine
|
December 19, 2024
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib
Alan Barnicle, Isabelle Ray-Coquard, Etienne Rouleau, et al.
Journal for Immunotherapy of Cancer
|
June 15, 2022
Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab
Geoffrey Alan Watson, Enrique Sanz-Garcia, Wen-Jiang Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 30, 2020
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)
Neesha C Dhani, Hal W Hirte, Lisa Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 23, 2017
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization
Stephanie Lheureux, Zhongwu Lai, Brian A Dougherty, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 7, 2021
Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced Cancer
Camilla Zimmermann, Ashley Pope, Breffni Hannon, et al.
Page
of 14